John M. Leonard, President and CEO of Intellia Therapeutics, Inc. (NASDAQ:NTLA), filed a Form 4 on August 24, 2026, reporting the sale of common stock on August 20 and August 21, 2026, executed automatically under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • August 20 sale: Leonard disposed of 19,890 shares of common stock at a weighted average price of $12.60, with individual transaction prices ranging from $12.32 to $13.00, inclusive.
  • August 21 sale: Leonard disposed of 2,785 shares at $13.00 per share.
  • Remaining direct ownership: Following the August 21 transaction, Leonard directly held 1,147,064 shares of common stock.
  • Indirect holdings: Leonard also holds 58,415 shares indirectly through the John M. Leonard 2015 Irrevocable Trust.
  • 10b5-1 plan: According to the filing, both sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by Leonard on May 21, 2026.

Intellia Therapeutics CEO Stock Transactions: Details From the Filing

The Form 4 filed by John M. Leonard, who serves as both a Director and President and CEO of Intellia Therapeutics, Inc., discloses two separate dispositions of common stock on consecutive trading days. The filing was signed by James Basta as attorney-in-fact and submitted on August 24, 2026.

The August 20, 2026 transaction involved the sale of 19,890 shares. The filing notes that the $12.60 price listed is a weighted average, as the shares were sold across multiple transactions at prices ranging from $12.32 to $13.00, inclusive. The filing states that full details on the number of shares sold at each separate price are available upon request from the Commission staff, the company, or a security holder. After this transaction, Leonard directly owned 1,149,849 shares.

On August 21, 2026, an additional 2,785 shares were sold at $13.00 per share, reducing Leonard's direct beneficial ownership to 1,147,064 shares. Both transactions carry transaction code "S" and are designated as disposals. The filing indicates both sales were made pursuant to a Rule 10b5-1 trading plan that Leonard adopted on May 21, 2026. In addition to his direct holdings, the filing reflects 58,415 shares held indirectly through the John M. Leonard 2015 Irrevocable Trust.

What Was Disclosed

The filing reports two sales of Intellia Therapeutics common stock by President and CEO John M. Leonard on August 20 and August 21, 2026, totaling 22,675 shares, executed under a Rule 10b5-1 plan adopted May 21, 2026. Direct beneficial ownership following the transactions stood at 1,147,064 shares.